Pharma Talks

Pharma Talks

por Nataliya Andreychuk
The AI Investment Producing the Wrong Results in Pharma | Pharma Talks with Nataliya Andreychuk
In this solo episode of Pharma Talks, Nataliya Andreychuk takes an unfiltered look at one of the biggest challenges emerging from AI adoption in the pharmaceutical industry: the velocity trap. Pharma is investing billions in artificial intelligence, accelerating content production, expanding into new channels, and making localization easier than ever. Yet at the same time, huge volumes of approved content are never used. Nataliya explores what happens when AI-powered content creation moves faster than the workflows, relationships, and human expertise needed to make that content meaningful. She looks at the gap between content production and HCP engagement, the role of AI-native pharma organizations, and why AI may be exposing β€” rather than solving β€” broken pharmaceutical content workflows. The conversation also introduces the HUMICS framework and explores the uniquely human capabilities that will become even more important in an AI-native pharmaceutical organization. 00:00 Welcome to a solo episode of Pharma Talks 00:07 Pharma’s massive AI investment and the race for efficiency 02:00 The AI content β€œvelocity trap” 04:00 Why more content doesn’t necessarily mean more engagement 06:00 AI-native pharma and the future of human expertise 08:00 The HUMICS framework 10:00 Human-in-the-loop, MLR and compliant AI 12:00 The AI roadmap pharma leaders should be building πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk. πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/
AI-Native Talent: The Future of Pharma Jobs & Recruitment | Pharma Talks with Nataliya Andreychuk
Steve Swan returns to Pharma Talks for a conversation about what has changed in pharma talent and recruitment since his last conversation with Nataliya Andreychuk a year ago. And the answer is: a lot. AI is now writing job descriptions, tailoring resumes, screening candidates β€” and, in some cases, essentially creating an AI-versus-AI recruitment loop. The result? Hundreds of polished applications, but not necessarily more people who can actually do the job. With nearly 30 years of experience hiring across pharma and biotech, Steve shares what he is seeing from the front lines β€” from the growing demand for AI talent to the rise of "AI-native" professionals and the new role of humans in an increasingly AI-driven workplace. Chapters: 0:00 AI is already changing recruitment 4:13 The AI recruitment loop: when AI starts checking its own homework 11:37 Are AI-native professionals the next generation of pharma talent? 15:05 The "bionic employee" and why human intelligence still matters 19:38 Hot or Not: Is pharma already losing the AI talent race? 24:32 Can pharma compete with Big Tech for AI talent? 25:06 Where will the next pharma talent wave come from? πŸ“² Enjoyed this episode? πŸ‘‰ Like, subscribe & hit the πŸ”” to never miss a Pharma Talks episode. πŸ‘‰ Have a question about hiring, recruiting or building AI talent in pharma and biotech? Send it our way β€” we're listening. πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™οΈ Steve Swan β†’ https://www.linkedin.com/in/swangroup/
Commercial and Medical Alignment in Pharma | Pharma Talks with Nataliya Andreychuk | Part 2
Part 2 of this Pharma Talks conversation with Elaine Gamble moves from identifying the challenges of Commercial and Medical collaboration to the practical steps organizations can take to create connected customer experiences. The discussion explores how AI, next best action, customer data, and organizational culture can help pharma teams work as one β€” without compromising compliance or scientific integrity. πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode. πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk. πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™οΈ Elaine Gamble β†’ https://www.linkedin.com/in/elainegamble/
Commercial and Medical Alignment in Pharma | Pharma Talks with Nataliya Andreychuk | Part 1
Elaine Gamble, customer engagement leader, omnichannel strategist, and former executive at Merck, Novartis, Otsuka, and other leading pharmaceutical companies, joins Nataliya Andreychuk on Pharma Talks to explore why stronger collaboration between Commercial and Medical has become essential for delivering connected, compliant, and customer-centric engagement. In Part 1, Elaine explains why silos still exist despite years of digital transformationβ€”and why technology isn't the biggest barrier. Key takeaways: Commercial and Medical teams often share the same goals but operate through transactional relationships instead of true collaboration. Leadership, culture, and shared initiatives β€” not incentives alone β€” are the foundation of effective cross-functional alignment. MSL insights remain one of pharma's most underutilized assets and can significantly improve commercial engagement when shared appropriately. AI, orchestration, and omnichannel capabilities already exist to support collaboration β€” but many organizations are still underusing them. The future of customer engagement depends on seeing one healthcare professional through one connected customer journey. Discover how leading pharma organizations can move beyond silos and build stronger Commercial and Medical partnerships that create more meaningful healthcare professional experiences. Explore why pharma needs stronger Commercial and Medical collaboration to deliver connected, compliant, and customer-centric engagement. πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode. πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk. πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™οΈ Elaine Gamble β†’ https://www.linkedin.com/in/elainegamble/
AI in Pharma Omnichannel: From Strategy to Execution l Pharma Talks with Nataliya Andreychuk l Part 2
Part 2 of this Pharma Talks conversation with Matteo Colonna picks up where strategy meets execution β€” moving from the "why" of omnichannel and AI to the practical realities of making it work inside pharma organizations. πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™οΈ Matteo Colonna β†’ https://www.linkedin.com/in/colonnamatteo/
AI in Pharma Omnichannel: From Strategy to Execution l Pharma Talks with Nataliya Andreychuk l Part 1
Matteo Colonna, an omnichannel transformation practitioner with a background in theoretical physics from Sapienza University in Rome and experience across consulting, digital agencies, and two major pharma companies, joins Nataliya Andreychuk on Pharma Talks to unpack why omnichannel and AI have moved from "nice to have" to business necessity. Key takeaways: Customer behavior and expectations have fundamentally shifted β€” pharma companies can no longer design omnichannel experiences without first understanding what customers actually need and prefer. Technology should never be the starting point β€” the right approach begins with identifying the business or customer problem, then working backward to the technology that solves it. Omnichannel and AI transformation is no longer a technology project β€” it's a full business transformation that touches strategy, structure, and mindset. Real omnichannel execution requires bridging strategy and day-to-day operations, not just designing frameworks on paper. Explore how pharma teams move from omnichannel strategies to execution and where AI creates real value across content, insights, and engagement. πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™οΈ Matteo Colonna β†’ https://www.linkedin.com/in/colonnamatteo/
The Impact of AI on Jobs l Pharma Talks with Nataliya Andreychuk
Karol Wolak, Director and Global Omnichannel Excellence Lead at Merck, joins Nataliya Andreychuk on Pharma Talks to tackle a question on everyone's mind: is AI coming for pharma jobs? His perspective is grounded in hands-on work across customer engagement and digital transformation at one of the industry's largest organizations. Views shared are Karol Wolak's own and do not represent an official position of Merck. Key takeaways: AI isn't replacing pharma roles anytime soon β€” it's better positioned to absorb repetitive back-office work like content tagging, MLR approval, and data collection. Human qualities β€” context, ethics, judgment, empathy β€” remain outside what AI can deliver, especially in a highly regulated industry. The environmental cost of AI, from data storage to energy consumption, is a factor the industry rarely puts on the table. Patient-centricity stays the anchor point for every engagement decision, regardless of which technology sits behind it. Staying engaged and experimenting with AI beats waiting on the sidelines β€” but balance matters more than volume. Chapters: 0:00 Cold open β€” "AI will not replace us, at least not now" 0:51 Karol Wolak on the shift from multichannel to omnichannel at Merck 1:49 Why patients are the real center of pharma engagement 3:33 Does AI take our jobs? The blunt answer 5:02 Resource optimization: where AI actually helps pharma teams 7:14 The environmental cost of AI no one talks about 9:18 Finding the balance between innovation and human survival 13:06 Advice for listeners: don't wait on the sidelines πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik) πŸ”— Follow & Connect: πŸŽ™οΈ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™οΈ Karol Wolak β†’ https://www.linkedin.com/in/karolwolak/
Agentic AI in Pharma: Are We Ready for AI That Acts? l Pharma Talks with Nataliya Andreychuk
Agentic AI has moved pharma from answering questions to autonomously orchestrating entire workflows β€” but most organisations are still building the foundations it needs to run well. In this episode, Nataliya Andreychuk talks with Michal Dojlidko about what agentic AI actually requires in practice: the right data, the right guardrails, continuous upskilling, and a clear-eyed view of where humans still belong in the loop. Key topics Evolution of AI in pharma from answering questions to autonomous workflows Importance of trust and data foundations in AI adoption Regulatory considerations and human oversight in agentic AI Future roles of humans as strategists and overseers of AI Technological advancements enabling secure, scalable AI solutions Chapters 00:00 Introduction to Agentic AI in Pharma Marketing 00:55 Evolution of AI in Pharma 02:34 The Shift to Autonomous AI 03:49 Reimagining Workflows with AI 05:10 Building Trust in AI 06:23 Data Foundations for AI Success 07:47 Continuous Learning and AI Literacy 09:31 The Future Role of Humans in AI 12:19 Security and Compliance in AI 14:11 Human Oversight in Regulated Industries 15:56 Hot or Not: AI Statements 23:45 Conclusion and Key Takeaways Discover more platforms to listen to this podcast: https://rss.com/podcasts/pharma-talks/ *** Follow Viseven, Nataliya, and Michal in social media: https://www.linkedin.com/company/2907491 https://www.linkedin.com/in/andreychuk/ https://www.linkedin.com/in/mdojlidko/
How to Build an Omnichannel Strategy in Pharma l Pharma Talks with Nataliya Andreychuk
Michael Kirzhner, Omnichannel Platforms and Capabilities Leader at AbbVie, joins Nataliya Andreychuk to discuss the real state of omnichannel in pharma β€” what the industry has built, what's still missing, and where the next evolution lies. Michael has spent over a decade navigating the shift from field-centric models to digital-first orchestration inside one of the world's largest pharma companies. In this episode: Omnichannel fragmentation starts with departments, not technology β€” the coordination layer is what pharma hasn't built yet Most companies are strong at functional execution but lack a central decisioning function that cuts across channels Digital opinion leaders are outpacing traditional KOLs because they've mastered the channels pharma is still learning Patient services is facing the same orchestration challenge commercial solved β€” and the stakes are higher AI's real value isn't automation β€” it's closing the gaps in personalization, decisioning, and content throughput that were previously impossible at scale πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik) πŸ”— Follow & Connect: πŸŽ™ Nataliya Andreychuk β†’ https://www.linkedin.com/in/andreychuk/ πŸŽ™ Michael Kirzhner β†’ https://www.linkedin.com/in/michaelkirzhner/
Pharma Talks with Nataliya Andreychuk | Live from NEXT Pharma Summit | Jennifer Cleall
In this episode of Pharma Talks, recorded live at NEXT Pharma Summit in Dubrovnik, Nataliya Andreychuk speaks with Jennifer Cleall, Global Head of Digital Transformation at Ferring Pharmaceuticals, on what it actually takes to align medical and commercial teams β€” and where AI fits into that picture. Jennifer brings cross-industry perspective spanning pharma, med tech, and enterprise technology. Key takeaways: AI won't take our jobs β€” but being deliberate about where and why you apply it is what separates progress from noise Before layering in AI, organizations need to simplify processes and systems first β€” technology won't fix broken foundations AI can act as an enabler for medical-commercial alignment, but directional clarity on where you're headed has to come first The goal hasn't changed: showing up with relevance and trust for HCPs to improve patient outcomes Digitizing what exists today is not the destination β€” the real question is where pharma needs to be in five to ten years πŸ“² Enjoyed this episode? πŸ‘‰ Like, Subscribe & hit the πŸ”” to never miss a Pharma Talks episode πŸ‘‰ Want to be a guest? Plan your recording with Nataliya Andreychuk: https://www.linkedin.com/in/andreychuk/
1 de 5